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Abstract
 
Activation of B cells by antigen fuels two distinct molecular modifications of immunoglobulin
(Ig) genes. Class-switch recombination (CSR) replaces the Ig
 
 
 
 heavy chain constant region
with a downstream constant region gene, thereby altering the effector function of the resulting
antibodies. Somatic hypermutation (SHM) introduces point mutations into the variable regions
of Ig genes, thereby changing the affinity of antibody for antigen. Mechanistic overlap between
the two reactions has been suggested by the finding that both require the activation-induced
cytidine deaminase (AID). It has been proposed that AID initiates both CSR and SHM by ac-
tivating a common nuclease. Here we provide evidence that cells lacking AID, or expressing a
dominant negative form of the protein, are still able to incur DNA lesions in SHM target se-
quences. The results indicate that an intact cytidine deaminase motif is required for AID func-
tion, and that AID acts downstream of the initial DNA lesions in SHM.
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Introduction
 
One of the hallmarks of the immune system is the ability to
recognize large numbers of antigens. In the mouse and hu-
man B cell repertoires, diversity is generated by two dis-
tinct processes; the primary repertoire is generated in the
bone marrow by V(D)J recombination (1). Its further di-
versification involves the antigen-driven introduction of
point mutations into the V regions of Ig genes (1). This
process of somatic hypermutation (SHM) gives rise to fam-
ilies of related mutant antibodies which are then selected
for their binding affinity to the immunizing antigen (2).
During hypermutation, the V regions of Ig genes accu-
mulate single nucleotide substitutions and occasional inser-
tions and deletions. Many of the mutations occur at specific
residues (hotspots), suggesting that the sequence surrounding
a hotspot might be the target of a putative mutator complex
(3). Yet whenever the V gene has been replaced with artifi-
cial substrates, those substrates hypermutate successfully (3),
and so the sequence of the V gene itself does not initiate the
mutation process. Surprisingly, the specific V region pro-
moter can be replaced by heterologous promoters without a
detrimental effect on hypermutation (3), but the process is
absolutely dependent on the presence of the Ig enhancers.
Because of this reliance on promoter and enhancer elements,
it is has been suggested that the targeting step of hypermuta-
tion is linked to transcription, although whether it is coupled
to the transcription process per se or to a general require-
ment for locus accessibility remains unclear (4–6).
SHM was originally hypothesized to be a two-step pro-
cess, initiated by cleavage of the DNA within the mutating
region, and subsequently resolved by error-prone repair
(7). There is strong circumstantial evidence to suggest that
the cleaved DNA intermediate is a DNA double-strand
break, as V regions of hypermutating cells incur DSBs on
hotspots and at high rates (8, 9). Furthermore, the initiation
of DSB formation has been shown to require the same ele-
ments which regulate the introduction of mutations (tran-
scription and the presence of the enhancer) (8, 9). These
hypermutation-associated DSBs are abundant in the G2
(postreplicative) phase of the cell cycle, and thus it has been
suggested that they are repaired by homologous recombi-
nation between sister chromatids (8).
Even though it has been extensively studied, little is
known about the molecular mechanism of the SHM pro-
cess. The only known protein whose loss of function leads
to a significant downregulation (if not total ablation) of hy-
permutation is the recently discovered activation-induced
cytidine deaminase (AID) (10, 11). Yet, the function of
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AID in somatic hypermutation is far from clear, and its ef-
fect might not even be direct, as AID is thought to be an
RNA-editing enzyme (12). It has been postulated that AID
edits the mRNA of the endonuclease responsible for the
DNA lesions in both CSR and SHM (10). Alternatively,
AID might be responsible in editing the mRNA of a factor
(or factors) responsible for orchestrating DSB repair. Here
we report that SHM-associated DSBs are still present in
cells lacking AID, or expressing a dominant negative form
of the protein. Our results indicate that AID acts down-
stream of the initial DNA lesions in SHM, possibly by edit-
ing the RNA of a repair factor.
 
Materials and Methods
 
Plasmid Constructs.
 
The AID cDNA was amplified from Ra-
mos cDNA and the H56R/E58Q mutations in AID were intro-
duced with the QuikChange™ kit (Stratagene). To generate the
bacterial expression vectors, AID or AID DN were indepen-
dently cloned into pET3d in frame with GST, to generate the
wild-type GST-AID or GST-AID DN fusion gene, respectively.
The proteins were expressed in BL21 
 
 
 
DE3 cells and purified
with glutathione sepharose 4B resin, according to the manufac-
turer’s instruction (Amersham Pharmacia Biotech).
To generate the retroviral expression vectors, the AID DN
cDNA was cloned into the pMSCV retroviral expression vector
(CLONTECH), engineered to express either GFP or a puromy-
cin resistance gene from an internal phosphoglycerol kinase (pgk)
promoter.
 
Mice and Cell Culture.
 
AID
 
 
 
/
 
 
 
 (10) mice have been de-
scribed previously. The Ramos (RA-1) cell line was obtained
from the American Type Culture Collection and grown as de-
scribed previously (13). For retroviral infections, pMSCV or pM-
SCV-AID DN, along with the packaging plasmid pkat (14), were
cotransfected into 293T cells by calcium phosphate precipitation
and viral supernatants harvested 48 h after transfection were used
to infect cells.
 
Deamination Assay.
 
The deamination assay was performed as
described previously (15). Briefly, 100 
 
 
 
g of protein was added to
a mix containing 25 
 
 
 
mol Tris-HCl, pH 7.05, and 1 
 
 
 
mole cyti-
dine (1 ml final volume). At different times, 100 
 
 
 
l samples were
added to 900 
 
 
 
l of 0.5 M ice-cold perchloric acid and the mix-
ture was centrifuged. The absorbance of the supernatant was
measured at 290 nm. Under these conditions, the difference in
the molar extinction coefficient between cytidine and uridine is
10.1 
 
 
 
 10
 
6
 
 cm
 
2
 
 per mol (15).
 
LM-PCR and RT-PCR.
 
Cells were embedded in agarose
and genomic DNA prepared as described previously (8). The
sequences of gene specific primers not described in (8) were as
follows: mouse VH186.2, VH186.2 L1 TTCTTGGCAGCAA-
CAGCTACAGGTAAGG VH186.2 L2 GCAGGCTTGAG-
GTCTGGACATATACATG probe GACATCCACTTTGC-
CTTTCTCTCCACAGGTG; mouse V
 
 
 
1, V
 
 
 
1 L1 GTT-
GTGACTCAGGAATCTGCACTCACC V
 
 
 
1 L2 GGTGAAA-
CAGTCACACTCACTTGTCGC probe GTACTGGGGCT-
GCTACAACTAGTAACTATGCCAACTG; and mouse C
 
 
 
,
C
 
 
 
 L1 GCTTCCCATCAGTCCTGAGAG C
 
 
 
 L2 CCACCT-
CACAGGTGCTGCTGCCTTCC probe CACGTGGTGTG-
CAAAGTCCAGCACC. Total Ramos RNA was prepared using
RNAsol (Tel-Test, Inc.), treated with DNase, and reverse tran-
scribed using random nonamers. c-myc, and human AID were
PCR amplified (30 cycles) from cDNA from 10
 
5
 
 cells using hot-
start Taq (QIAGEN) and combinations of the following primers:
human AID, hAID left GTCCGCTGGGCTAAGGGTCGGCG
hAID right GCACCCCGGCGCGGTGCAGCCG; and human
c-myc, c-myc left CCGCCCGCGGCCACAGCGTC c-myc
right CGCCTCTTGACATTCTCCTCGGTGTC.
 
Flow Cytometry and Cell Sorting.
 
To purify germinal center B
cells, we pooled spleens from mice at 14 d after immunization
with NP-CGG in alum (Biosearch Technologies, Inc.), and sepa-
rated the resting and activated lymphocytes on a Percoll gradient
(Amersham Pharmacia Biotech). Cells were stained with the
pan-B cell marker B220 (phycoerythrin) and the B/T activated
cell marker GL-7 (FITC) (both from BD PharMingen), and
sorted on a Becton Dickinson FACSVantage™. Sorted cells were
immediately embedded in agarose for further analysis. For the cell
cycle study, standard methods were used (16). All analyses of flow
cytometric data were performed using the FlowJo™ software
package (Treestar).
 
Results
 
An AID Catalytic Mutant Has No Deaminase Activity.
 
The primary sequence of AID shares highest sequence sim-
ilarity with Apobec-1 (12) (Fig. 1 A), the prototypic RNA-
editing cytidine deaminase (14). Cytidine deaminases in
general share a conserved active site motif consisting of a
histidine and two cysteines which coordinate Zn
 
2
 
 
 
, and a
glutamate which serves as a proton donor in the deamina-
tion reaction (17). Replacement of any of these four amino
acids results in a catalytic mutant (18). We generated an
AID protein mutated in two of these residues (H56R/
E58Q) and expressed both the mutant and wild-type pro-
teins in 
 
Escherichia coli
 
. The wild-type protein was active in
an in vitro deamination assay while the catalytic mutant
was not (Fig. 1 B).
All except one of the known cytidine deaminases act as
homodimers or homotetramers (19), and hence catalytic
mutants can have a dominant negative effect (19, 20). A se-
ries of leucines in the carboxy terminus of Apobec-1 is
thought to be important for dimerization (20), and even
though there is low sequence homology between AID and
Apobec-1 in that region, these leucines are conserved in
AID. Furthermore, secondary structure prediction algo-
rithms (21) model the carboxy terminus as almost entirely
 
 
 
-helical with a potential for coiled coil formation (Fig. 1
C). Hence the H56R/E58Q mutant AID (henceforth AID
DN) might display a dominant negative phenotype.
 
AID DN Interferes with SHM.
 
To determine the effect
of the putative dominant negative protein on SHM, we ex-
pressed the protein in the human Burkitt lymphoma cell
line Ramos, which hypermutates constitutively in culture
(13). Cells were infected with a retrovirus expressing hu-
man AID DN from the long terminal repeat promoter and
a puromycin resistance gene (puro) from an internal pgk
promoter. Infected cells selected with puromycin expressed
AID DN at levels 20-fold higher than endogenous AID, as
assessed by semiquantitative RT-PCR (Fig. 2 A). As con-
trols, cells were infected with retroviruses expressing only
the puro gene (designated “empty”) or wild-type AID in
addition to puro. Infected cells (puromycin resistant) were 
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seeded at single cell density, and after 6 wk of expansion,
the Ig heavy chain variable region was PCR amplified,
cloned, and sequenced. We assayed six clones infected with
the empty retrovirus, and in all cases, 4–6 independent mu-
tations were identified (Fig. 2 B), yielding a mutation fre-
quency of 0.5 
 
 
 
 10
 
 
 
5
 
/bp/generation (calculated as per
Capizzi and Jameson; for a review, see reference 22). The
results from the analysis of clones infected with wild-type
AID retrovirus were comparable (data not shown). In con-
trast, Ramos clones expressing AID DN contained virtually
no mutations (Fig. 2 B), yielding a mutation frequency at
least 20-fold lower than that of cells infected with the
empty virus (0.02 
 
 
 
 10
 
 
 
5
 
/bp/generation). We conclude
that expression of AID DN suppresses SHM (presumably
by interfering with the function of the wild-type protein),
yielding a phenotype functionally equivalent to full AID
deficiency. The results also indicate that an intact cytidine
deaminase catalytic motif (and therefore deaminase activity)
is essential for the function of AID.
 
SHM-associated DSBs Are Not Affected by Expression of
AID DN.
 
Ramos cells were infected with retroviruses
that expressed either puromycin alone (empty virus), or
puromycin in conjunction with wild-type AID or AID
DN, selected in the antibiotic, and assayed for DSBs in the
Ig heavy and light chain variable regions. Consistent with
our previous report (8), we can titrate the number of
linker-ligated genomes down to 50 and still detect DSBs in
Ramos cells infected with the empty virus or with the
wild-type AID virus (Fig. 3 A and data not shown). Ramos
cells infected with the AID DN retrovirus continue to in-
Figure 1. Characterization of recombinant AID proteins. (A) Alignment of the predicted active site of AID and the active site of Apobec-1. Con-
served catalytic residues are indicated in red. (B) Cytidine deamination assay. Recombinant GST-AID wild-type (WT) and GST-AID DN mutant were
expressed in and purified from bacteria. CTP was incubated with purified GST-AID WT, GST-AID DN, or BSA, and the amount of substrate remain-
ing at different time points was determined by absorption at 290 nm. The experiment was repeated with AID DN tagged with a minimal tag (strep tag,
Cell Genesys) with similar results (data not shown). (C) Secondary structure prediction for human AID. C (gray) indicates potential loops (or nonstruc-
tured regions), E (yellow) indicates a  -sheet, and H (blue) indicates an  -helix (modeling was done on the 3D-PSSM server; reference 21).
Figure 2. AID DN interferes with SHM. (A) RT-PCR analysis of
AID expression levels in wild-type Ramos cells (left) and Ramos cells
transduced with an AID-DN–expressing retrovirus (right). Amplification
of c-myc controls for input cDNA. (B) IgH variable region mutations per
culture after 6 wk of expansion (based on 48 sequences per culture). Cul-
tures were grown from single Ramos cells transduced with empty virus or
with AID-DN–expressing virus. 
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cur DSBs over the Ig heavy variable region, at a similar or
even slightly higher frequency than uninfected cells or
those infected with the empty virus (bands are reproducibly
detected with as few as 10 input genomes; Fig. 3 A and data
not shown). Similar results were obtained for the Ig
 
 
 
 vari-
able region (data not shown). Thus, interference with AID
function through expression of AID DN does not diminish
the amount of DSBs over the Ramos variable regions, even
though it dramatically reduces mutation accumulation.
DNA DSBs can be lethal to the cell if not repaired. Since
the introduction of mutations is thought to occur during
the repair of SHM-associated DSBs (8, 9), it was possible
that Ramos cells expressing AID DN (which have abun-
dant DSBs but very few mutations) would exhibit substan-
tial cell death. To investigate this possibility, we stained
Ramos cells with propidium iodide and analyzed them for
DNA content. The percentage of cells in the G1, S, and
G2 phases of the cell cycle did not vary significantly be-
tween Ramos cells infected with empty virus, wild-type
AID or the AID DN virus (Fig. 3 B and data not shown).
Importantly, no subdiploid peak indicative of dead cells
was observed in any of the cultures. Furthermore, neither
the proliferation rate nor the restriction of DSBs to the late
S/G2 phase of the cell cycle (8) was affected by AID DN
expression (data not shown). Thus, Ramos cells infected
with the AID DN retrovirus do not die as a result of unre-
solved DSBs, indicating that these DSBs are repaired but
predominantly in an error-free fashion.
 
SHM-associated DSBs Are Not Affected by Deletion of
AID.
 
Our data suggest that ablation of the catalytic activ-
ity of AID results in a dominant negative phenotype with
respect to SHM, but does not impair the formation of
SHM-associated DSBs. It is possible, however, that AID
has functions that do not depend on the cytidine deaminase
activity (for instance in facilitating DSB formation). To ex-
amine this possibility, we assessed Ig variable region DSBs
in activated B cells lacking AID. Wild-type and AID
 
 
 
/
 
 
 
C57BL/6 mice were immunized with NP-CGG, an anti-
gen preferentially recognized by a specific heavy and light
chain combination (V
 
H
 
186.2 and V
 
 
 
1) (23). At 14 d after
immunization, splenic B cells were collected and sorted
into germinal center (GC) and resting B cell populations.
We could reproducibly amplify DSBs over the V
 
H
 
186.2
and V
 
 
 
1 genes both from wild-type and AID
 
 
 
/
 
 
 
 cells (Fig.
3 C and data not shown). Such DSBs could be amplified
from both the GC and the resting B cell fractions, but were
preferentially present in the GC B cell population (10- to
100-fold higher frequency, Fig. 3 C, panels i and ii). The
observed DSBs were V region specific since no DSBs could
be amplified from the Ig 
 
 
 
 constant region or from the re-
combination activating gene (RAG)-1 gene (Fig. 3 C panel
iii, and data not shown). We conclude that in the absence
of AID, SHM-associated DSB formation remains intact
both in vitro and in vivo, and therefore, that AID likely
functions in a postcleavage step of the SHM process.
 
Discussion
 
The immune system generates diversity by using three
distinct mechanisms of genetic alteration. V(D)J recombi-
nation, CSR, and SHM. Mechanistically, all three pro-
cesses can be divided into at least three phases: targeting/
Figure 3. SHM-associated DSBs are not abrogated by AID DN or
AID deficiency. (A) LM-PCR amplification of DSBs from the endoge-
nous VH region of Ramos cells infected with empty virus or with AID
DN virus. Genome equivalents of linker-ligated template DNA are indi-
cated above the lanes, and the size of molecular weight markers to the
right (bp). (B) Cell cycle status analysis of retrovirally infected Ramos cells
using propidium iodide staining. The percentage of cells in G1, S, and G2
are indicated below the FACS® plots. The circle indicates the expected
location of apoptotic cells. (C) LM-PCR amplification of DSBs from the
VH186.2, V 1, and C  genes from C57BL/6 (WT) or AID /  mice 14 d
after immunization with NP-CGG. Resting (B220 , GL7 , small) and
activated (B220 ,GL7 , large) splenic B cells were compared. Genome
equivalents of linker-ligated template DNA are indicated below the lanes.
Standard PCR of C  (bottom panel) indicates that equivalent amounts of
DNA were used for each PCR reaction. 
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recognition, DNA cleavage, and repair (18). In all three
cases, transcription is thought to play a key role in targeting
of a nuclease to the Ig locus. The cleavage step is thought
to result in the production of a DNA DSB, though the cre-
ation of the DSB might not be the initial event. In V(D)J
recombination for instance, the initial event is the nicking
of one strand by the RAG recombinase, followed by hair-
pin formation and resolution into a blunt DSB (24). It is
not known whether the CSR nuclease initially inflicts a
single or double-strand break but there is some evidence to
suggest that the final product of cleavage is a DSB (25). Fi-
nally, there is data to indicate that SHM also involves the
creation of a DNA DSB, though that may not necessarily
be the first step of the cleavage reaction. Indeed, it is possi-
ble to amplify single-strand ends from hypermutating se-
quences (26), though whether the experiments in (26)
detect one of the two ends generated by a DSB or alterna-
tively, the unique end of a single-strand break remains un-
clear. Thus, regardless of the particular mechanics which
lead to the creation of the DSB, the end product of the
cleavage step of the reaction and hence, the substrate upon
which DNA repair must act, in all three cases is likely to be
a DNA DSB.
In vertebrates, the two main pathways of DSB repair are
homologous recombination and nonhomologous end join-
ing (NHEJ). These appear to operate predominantly in dis-
tinct phases of the cell cycle: G
 
1
 
/early S for NHEJ and late
S/G
 
2
 
 for homologous recombination (27). The DSBs asso-
ciated with V(D)J recombination are repaired by NHEJ
and are found almost exclusively in G
 
1
 
 phase cells. There is
evidence to suggest that NHEJ might be the repair mecha-
nism of choice for CSR-generated ends (25). In contrast,
SHM-associated DSBs are found in G
 
2
 
 phase cells and it has
been postulated that they are repaired by homologous re-
combination (8, 28). Yet, while SHM and CSR have been
proposed to involve distinct repair pathways, the end prod-
ucts of CSR (the switch joints) incur point mutations at
high frequency (29) suggesting either that a common error-
prone polymerase is involved in class-switch–associated
NHEJ repair as well as in SHM-associated recombinational
repair or that CSR repair requires both the NHEJ and the
homologous recombination machinery.
Mechanistic overlap between CSR and SHM is further
suggested by the finding that both reactions require AID
(10). As ablation of AID leaves the targeting stage (the gen-
eration of germline transcripts) of CSR intact (10), AID has
been proposed to function either at a pre or postcleavage
step. In an attempt to distinguish whether AID is responsi-
ble for editing the nuclease or for coordinating repair, Nus-
senzweig and colleagues have looked at the association of
repair factors with switch region DNA in wild-type or
AID
 
 
 
/
 
 
 
 
 
mice (30). The repair factors Nbs1 and histone
 
 
 
H2AX are known to accumulate in high concentrations
over areas which harbor DNA breaks, where they form
distinct nuclear “foci.” Such foci form readily over switch
regions in LPS-IL-4–stimulated wild-type B cells which in-
cur DNA breaks in the process of CSR, but are absent in
similarly stimulated, AID-deficient B cells (presumably be-
cause of the lack of DSB formation in the absence of AID).
Therefore in CSR, AID may act upstream of repair and
perhaps functions in initiating DSB formation (30).
If SHM and CSR were two different repair outcomes of
the similar DNA cleavage reactions as suggested previously
(30), the expectation would be that DNA lesions would be
absent in hypermutating sequences in AID-deficient cells.
Our results, however, provide evidence that cells lacking
AID, or expressing a dominant negative form of the pro-
tein, are still able to incur DNA lesions in SHM target se-
quences, which can be amplified and detected by ligation-
mediated PCR. Ramos cells overexpressing AID DN, and
germinal center B cells from AID
 
 
 
/
 
 
 
 mice, incur DSBs in
their Ig V regions without accumulating mutations (Fig. 3).
Furthermore, Ramos cells expressing AID DN do not die,
nor is their cell cycle perturbed, leading to the conclusion
that they must repair the abundant DSBs efficiently and ac-
curately (Fig. 2). Since AID
 
 
 
/
 
 
 
 
 
B cells are still able to incur
DNA DSBs over hypermutating sequences, either AID
plays different roles in SHM and CSR (for instance, by edit-
ing two separate mRNAs), or that DSBs are not mechanis-
tically linked to the SHM reaction. There is little doubt that
DSBs over hypermutating sequences are associated with the
process; they only occur over sequences which hypermu-
tate, they are extremely abundant, they coincide with muta-
tional hotspots, and they are present in the phase of the cell
cycle in which repair of SHM lesions probably occurs (10,
11, 13). However, it is possible that SHM is initiated by the
introduction of single-strand nicks which get converted into
mutations, and that the DSBs are formally not intermediates
but rather byproducts of that reaction (18). Even then, the
fact that DSBs are abundant over hypermutating sequences
in AID-deficient cells argues strongly that the formation of
the initial lesion (be it a nick or a DSB) as well as its poten-
tial byproducts is not dependent on the function of AID.
Thus, though both CSR and SHM employ AID, they
might do so in different steps of the two reactions.
We conclude that AID deficiency impairs SHM, but
does not affect the creation of the DNA breaks associated
with this process. Therefore, it is most likely that AID plays
a role in the postcleavage (repair) phase of this reaction. Its
action may transiently alter a DNA repair factor, thereby
creating an error-prone repair machinery capable of resolv-
ing SHM DNA lesions. Our experiments further suggest
that the cytidine deaminase catalytic core of AID is crucial
for its role in SHM. Thus if AID is an RNA-editing deam-
inase, its role in SHM is most likely to edit the RNA of a
DNA repair factor.
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